Q4 EPS Forecast for Core Laboratories Lifted by Analyst

Key Points

• Zacks Research raised Core Laboratories’ Q4 2027 EPS forecast to $0.24 from $0.23 and estimates Q1 2028 EPS at $0.11. Full-year earnings are currently expected at $0.56 per share.
• Core Laboratories’ latest quarterly results beat expectations, reporting $0.11 EPS versus the $0.09 consensus, though revenue fell 4.3% year over year to $124.61 million and missed estimates.
• Analyst sentiment has improved to a “Moderate Buy”, with an average price target of $21.00 versus the stock’s recent $12.29 opening price. CEO Lawrence Bruno also purchased 5,000 shares, while institutional investors own 97.81% of the stock.

Core Laboratories Inc. (NYSE:CLB - Free Report) - Equities research analysts at Zacks Research lifted their Q4 2027 earnings per share (EPS) estimates for Core Laboratories in a research note issued on Wednesday, August 19th. Zacks Research analyst Team now anticipates that the oil and gas company will post earnings of $0.24 per share for the quarter, up from their prior estimate of $0.23. The consensus estimate for Core Laboratories' current full-year earnings is $0.56 per share. Zacks Research also issued estimates for Core Laboratories' Q1 2028 earnings at $0.11 EPS.

Core Laboratories (NYSE:CLB - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The oil and gas company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. Core Laboratories had a return on equity of 10.03% and a net margin of 5.10%.The company had revenue of $124.61 million for the quarter, compared to analyst estimates of $126.26 million. During the same quarter in the previous year, the company posted $0.19 earnings per share. The firm's revenue was down 4.3% compared to the same quarter last year. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS.

CLB has been the subject of a number of other research reports. Johnson Rice upgraded shares of Core Laboratories from a "hold" rating to a "buy" rating and set a $21.00 price target for the company in a research note on Thursday, August 13th. Wall Street Zen raised Core Laboratories from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. Finally, Weiss Ratings raised Core Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, August 3rd. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $21.00.

Core Laboratories Stock Performance

Shares of CLB opened at $12.29 on Friday. The company's 50 day simple moving average is $11.53 and its 200-day simple moving average is $14.47. The firm has a market cap of $563.87 million, a PE ratio of 21.95, a price-to-earnings-growth ratio of 2.91 and a beta of 1.03. Core Laboratories has a 12-month low of $9.79 and a 12-month high of $20.36. The company has a current ratio of 2.12, a quick ratio of 1.55 and a debt-to-equity ratio of 0.41.

Institutional Investors Weigh In On Core Laboratories

Institutional investors have recently made changes to their positions in the stock. Summit Securities Group LLC acquired a new stake in shares of Core Laboratories in the first quarter valued at about $31,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Core Laboratories during the 4th quarter worth approximately $34,000. Quarry LP grew its holdings in shares of Core Laboratories by 118.1% in the 3rd quarter. Quarry LP now owns 2,953 shares of the oil and gas company's stock worth $36,000 after acquiring an additional 1,599 shares during the period. CWM LLC increased its stake in Core Laboratories by 36.1% in the 4th quarter. CWM LLC now owns 2,516 shares of the oil and gas company's stock valued at $40,000 after purchasing an additional 668 shares in the last quarter. Finally, Hantz Financial Services Inc. boosted its position in Core Laboratories by 124.7% during the fourth quarter. Hantz Financial Services Inc. now owns 3,177 shares of the oil and gas company's stock worth $51,000 after purchasing an additional 1,763 shares in the last quarter. 97.81% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Core Laboratories

In other Core Laboratories news, CEO Lawrence Bruno acquired 5,000 shares of the company's stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average price of $10.78 per share, with a total value of $53,900.00. Following the completion of the acquisition, the chief executive officer directly owned 262,438 shares of the company's stock, valued at approximately $2,829,081.64. The trade was a 1.94% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 1.26% of the stock is currently owned by company insiders.

Core Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Monday, August 10th will be issued a $0.01 dividend. This represents a $0.04 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, August 10th. Core Laboratories's dividend payout ratio (DPR) is currently 7.14%.

About Core Laboratories

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company's portfolio spans two primary service lines: reservoir description and production enhancement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source